Emily Leproust

Former CEO, Twist Bioscience

Search every verified Emily Leproust interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. At the SynBioBeta 2026 conference, Emily Leproust discussed the growth and strategy of Twist Bioscience, the DNA synthesis company she co-founded and leads as CEO. She noted that the company reported $111 million in quarterly revenue with 20% growth, a gross margin of more than 52%, and stated that the company expects to be profitable in September 2026. Leproust attributed the company's success to its team, saying "if it's good at Twist is the team. If it's bad, it's me." She described the company's approach as meeting customers where they are in their science, offering customized DNA, protein, and data services. Leproust reflected on the company's evolution since launching its first product in 2015, noting that the initial assumption that all customers wanted the same DNA product proved incorrect. She said the company had to "massively customize everything" because no two orders were the same, leveraging software and industrialization to serve diverse customer needs in drug discovery and other applications.